To characterize the disease course and visual outcome of uveitis in juvenile Behçet's disease (BD) compared with adults. The study population included 13 children (mean age 14±2.4 years; 22 eyes ...

Targeted exonic sequencing of candidate genes We selected 132 candidate genes that had been reported or suspected to play a role in the pathogenesis of Behcet’s uveitis (Supplementary Table S1).

Behçet's disease is an inflammatory disorder, with recurrent attacks of acute multisystem vasculitis. 1 Prevalence is highest among people of Middle Eastern or Far Eastern ancestry. Diagnosis of ...

August 29, 2012 — The US Food and Drug Administration (FDA) has granted orphan drug status to gevokizumab (Xoma 052, Xoma Corp), a monoclonal antibody that binds strongly to interleukin 1β (IL ...

Servier has received authorization to initiate a phase 3 clinical trial in several European countries to analyze the efficacy and safety of gevokizumab compared with placebo in reducing the risk ...

Self-reported general health was more impaired than visual function among patients with Behçet's uveitis, according to a study. "Several demographic and clinical variables had a significant ...

Available treatments for Behcet's uveitis are limited to corticosteroids and off-label use of immunosuppressive drugs, which can have significant side effects especially when used on a chronic basis.

Wedbush Securities expects cash runway for XOMA Ltd. (NASDAQ: XOMA) through start of phase 3 Behcet’s Uveitis study by year-end 2011. The brokerage maintained its outperform rating on shares of Xoma ...